Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
In a laboratory outside Cambridge sits a remarkable “biological computer”. Its 200,000 human brain cells, grown in the lab, lie on silicon circuitry that communicates their synchronised electrical activity on a screen to the outside world.
The CL1 device, about the size of two shoe boxes, was developed by Australian start-up Cortical Labs with the UK’s bit.bio, in a bid to create “synthetic biological intelligence” — a new form of computing that could offer opportunities beyond conventional electronics and other developing technologies such as quantum.
“Like our brains, biological computers will consume many orders of magnitude less energy than conventional electronics as they process information. Future applications could include robotics, security and the metaverse,” Cortical Labs chief executive Hon Weng Chong told the Financial Times.
The fast-growing search for alternatives to energy-intensive conventional electronics has stimulated the new field of biological computingwhich aims to tap directly into the intelligence of brain cells rather than simulating it in silicon through “neuromorphic” processing and AI.
Cortical Labs is at the forefront of this movement, though academic groups and other start-ups such as Swiss group FinalSpark and Biological Black Box in the US are also making progress.
Early applications of CL1 are in neuroscience and pharmaceutical research, discovering how different chemicals and drug candidates affect the brain cells’ information processing.
“The next stages of innovation will make possible new and more advanced forms of computation beyond conventional AI systems, using the same processors — neurons — that underpin intelligence in living organisms,” added Chong.
For Mark Kotter, clinical neuroscience professor at Cambridge university and bit.bio founder, the significance of CL1 “is that it is the first machine that can reliably assess the compute power of brain cells. That is a real paradigm shift.”
Experts noted that CL1 was a “remarkable achievement”, that has helped advance the fledgling biological computing field.
Karl Friston, a neuroscience professor at University College London who has also collaborated academically with a number of Cortical Labs scientists, said it could be regarded as the first commercially available biomimetic computer.
“However, the real gift of this technology is not to computer science — at the moment. Rather, it is an enabling technology that allows scientists to perform experiments on a little brain.”
Professor Thomas Hartung of Johns Hopkins University in Baltimore, who is investigating “organoid intelligence” using cerebral organoids or mini-brains grown from stem cells, said the outstanding contribution of Cortical Labs was to develop virtual games-playing as a benchmark for biological computing.
CL1’s predecessor, called DishBrain, learned to play the simple video game Pong, in which it moved a virtual paddle up and down to deflect a ball.
Training involved giving the neurons a “reward” stimulus when they moved the paddle correctly, by applying electrical activity in the form of a sine wave, which the cells like. The “punishment” when they got it wrong was unpleasant white noise.
Experiments with DishBrain and CL1 show how different conditions affect the neurons’ information processing, measured by how well they play Pong. “We have treated them with chemicals that have an impact on our brains,” said bit.bio’s Kotter. “This machine shows for example that alcohol degrades your ability to compute.”
Another experiment compared the effect of three epilepsy treatments and found that one of them, carbamazepine, was superior in improving gameplay metrics.
“We are thinking a lot about how to program our biological computers,” said Chong. “One big question is how we represent digital information to these neurons.” The scientists are teaching the neurons the shapes of digits, he added, “and they are now starting to recognise that a nine is different from a four or a five.”
Cortical Labs and bit.bio lay down pure layers of two specific types of neuron on the silicon circuitry of the CL1 biocomputer — one to excite electrical activity and the other to damp it down. “The balance between acceleration and brakes is really important,” Chong said. The neurons are grown from stem cells derived originally from the human skin.
Others such as Switzerland’s FinalSpark are exploring biological computing with cerebral organoids. But bit.bio and Cortical Labs believe their layers of standardised neurons will give more reproducible results than organoids.
“Our neurons look very homogeneous,” said Tony Oosterveen who leads bit.bio’s brain cells work. “If you look at other technologies you will see huge variation. Our strength is to make pure populations.”
Whatever the long-term promise of biocomputing, its advocates concede that adoption for more general applications and AI lies decades in the future. One problem is to work out an efficient programming system.
Another is that the neurons can live only for a few months in a CL1, sustained by a constant liquid flow to supply nutrients and remove waste products.
“A downside of a system like this is that we haven’t worked out yet how to do memory transfer,” said Chong. “Once the system dies you have to start from scratch again.”
Chong is aware of the ethical concerns that could arise in the future if biological computers and neuron cultures develop the rudiments of consciousness.
At present, he said, “these systems are sentient because they respond to stimuli and learn from them but they are not conscious. We will learn more about how the human brain works but we do not intend to create a brain in a vat.”